Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDGJune 11, 2025Read article
Results from NEXUS interim analysis published in eClinicalMedicine, part of THE LANCET DiscoveryScienceJune 11, 2025Read article
Aura Biosciences Announces Proposed Public Offering of Common Stock and WarrantsJune 11, 2025Read article
Aura Biosciences Reports First Quarter 2025 Financial Results and Business HighlightsJune 11, 2025Read article
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of DirectorsJune 11, 2025Read article
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business HighlightsJune 11, 2025Read article
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology CongressJune 11, 2025Read article
Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral AdrenoleukodystrophyMarch 24, 2025Read article
Minoryx announces dosing of the first patient with leriglitazone in the phase 2a study in Rett syndrome (TREE study) 4 March 2025March 24, 2025Read article
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business HighlightsMarch 24, 2025Read article
